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Background: Electronic cigarettes have been developed and marketed in recent years as smoking substitutes.
However, no studies have evaluated their effects on the cardiovascular system. The purpose of this study was to
examine the immediate effects of electronic cigarette use on left ventricular (LV) function, compared to the
well-documented acute adverse effects of smoking.
Methods: Echocardiographic examinations were performed in 36 healthy heavy smokers (SM, age 36 ± 5 years) before
and after smoking 1 cigarette and in 40 electronic cigarette users (ECIG, age 35 ± 5 years) before and after using the
device with “medium-strength” nicotine concentration (11 mg/ml) for 7 minutes. Mitral flow diastolic velocities (E, A),
their ratio (E/A), deceleration time (DT), isovolumetric relaxation time (IVRT) and corrected-to-heart rate IVRT (IVRTc)
were measured. Mitral annulus systolic (Sm), and diastolic (Em, Am) velocities were estimated. Myocardial performance
index was calculated from Doppler flow (MPI) and tissue Doppler (MPIt). Longitudinal deformation measurements of
global strain (GS), systolic (SRs) and diastolic (SRe, SRa) strain rate were also performed.
Results: Baseline measurements were similar in both groups. In SM, IVRT and IVRTc were prolonged, Em and SRe were
decreased, and both MPI and MPIt were elevated after smoking. In ECIG, no differences were observed after device use.
Comparing after-use measurements, ECIG had higher Em (P = 0.032) and SRe (P = 0.022), and lower IVRTc (P = 0.011),
MPI (P = 0.001) and MPIt (P = 0.019). The observed differences were significant even after adjusting for changes in heart
rate and blood pressure.
Conclusions: Although acute smoking causes a delay in myocardial relaxation, electronic cigarette use has no
immediate effects. Electronic cigarettes’ role in tobacco harm reduction should be studied intensively in order to
determine whether switching to electronic cigarette use may have long-term beneficial effects on smokers’ health.
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Smoking is a major risk factor for cardiovascular disease
[1,2]. Although several pharmaceutical products are
available for smoking cessation, long term quit-rates are
relatively low [3]. Therefore, tobacco harm reduction
strategy and products have been developed, with the
main goal to reduce the amount of harmful substances
administered to the human body.
Electronic cigarettes have been introduced to the market
in recent years as an alternative-to-smoking habit. They
consist of a battery-part, a cartridge containing liquid and
an electrical resistance that is heated by activation of the
battery and evaporates the liquid. The liquid usually con-
tains glycerol, propylene glycol, water, nicotine and a var-
iety of flavours that the user can choose. By using this
device, nicotine is delivered to the upper and lower re-
spiratory tract without any combustion involved. Millions
of people are using electronic cigarettes worldwide; how-
ever, lack of clinical research has raised global debate, con-
troversy and serious public health concerns [4].
Several studies have shown that, even in healthy smokers,
acute smoking inhalation has significant adverse effects on
left ventricular (LV) myocardial function that can be de-
tected by echocardiography [5-7]. No study has ever evalu-
ated the effects of electronic cigarette use on cardiac
function; thus, the purpose of the current study was to in-
vestigate the acute effects of using an electronic cigarette
ad lib for 7 minutes on haemodynamic parameters and




The study sample consisted of consecutive healthy sub-
jects visiting our hospital for routine examinations that
volunteered to participate. All participants were asymp-
tomatic, had normal physical examination and resting
electrocardiogram and were not taking any medications.
Smokers (group SM) were included if they were smoking
for at least 5 years and were consuming at least 15 ciga-
rettes per day. The reason for including only heavy
smokers was that a study examining the characteristics
of electronic cigarette consumers showed that most elec-
tronic cigarette users were formerly heavy smokers [8].
Electronic cigarette users (group ECIG) were included if
they had quit smoking and were using electronic ciga-
rettes with nicotine-containing liquid for at least 1 month,
according to self-report. To avoid potential compensatory
effects from using lower nicotine-containing liquid, partic-
ipants were included if they were daily consumers of simi-
lar “strength” liquids (9-12 mg/ml nicotine concentration)
to that used in the study (11 mg/ml). Exclusion criteria
were: presence of any major risk factor for cardiovascular
disease (i.e. diabetes, hypertension, hyperlipidemia andfamily history of premature coronary artery disease), his-
tory of endocrine disorders, body-mass index > 30 kg/m2
and more than occasional alcohol intake. Additional ex-
clusion criteria were derived from the echocardiography
studies: elevated LV mass index (>115 g/m2 for males
and > 95 g/m2 for females), abnormal LV function (LV ejec-
tion fraction < 55%) and more than mild valve regurgitation.
In total, 81 subjects were eligible to participate. Three
smokers did not present for the scheduled evaluation.
One electronic cigarette user was excluded because of
moderate aortic regurgitation and ascending aorta dilata-
tion due to bicuspid aortic valve. One smoker was ex-
cluded due to mildly depressed ejection fraction and
hypokinesia of LV lateral wall. The final study sample
consisted of 76 subjects, 40 electronic cigarette users
(3 females) and 36 smokers (3 females). Written informed
consent was obtained from all subjects for participation in
the study, and the protocol was approved by the ethics
committee of Onassis Cardiac Surgery Center.
Materials
All smokers were asked to use one commercially-available
tobacco cigarette of the same nicotine (1.0 mg), tar
(10 mg) and carbon monoxide (10 mg) yields. Electronic
cigarette users were asked to use a commercially-available
device with liquid containing 11 mg/ml nicotine concen-
tration. The device used was an eGo-T battery (Nobacco,
Athens, Greece) with an eGo-C atomiser (Alter Ego,
Athens, Greece). It is considered a “second-generation”
device. Unlike cigarette-like devices which consist of a
small battery and a polyfil-containing atomiser (commonly
called “cartomiser”), the electronic cigarette used in this
study is a multi-piece system (Figure 1). It consists of a
650 mAh rechargeable lithium battery, delivering 3.5 volts
to the atomiser (measured by a volt-meter), and an atom-
iser consisting of 4 parts: the tank which stores the liquid
(capacity of approximately 1.1 ml), the atomiser body, the
atomiser head which includes the resistance, and the
atomiser cap. It is a manually-activated device, by pressing
a button; it does not produce any vapour when not acti-
vated by the user.
The electronic cigarette liquid used in the study con-
tained 11 mg/ml nicotine and is considered “medium
strength” according to manufacturer’s report (USA Mix
Med, formerly known as MLB-Med, Nobacco, Athens,
Greece). It is sold in 20 ml bottles. It was the only liquid
tested by an independent laboratory (National Center for
Scientific Research “Demokritos”, mass spectrometry and
dioxin analysis laboratory) at the time of study initiation
[9]. According to the laboratory report, the contents were:
propylene glycol (α -propylene glycol or 1,2-propanediol)
in a concentration > 60%, linalool (3,7-dimethylocta-1,
6-dien-3-ol) in a concentration < 5%, nicotine (<10%),
tobacco essence (<5%), and methyl vanillin (4-hydroxy-
Figure 1 Electronic cigarette device and liquid used in the study.
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nitrosamines or polycyclic aromatic hydrocarbons were
detected.
For every participant, a new cartridge and atomiser head
was used. One of the researchers filled the cartridge with
1 ml of liquid; subsequently it was positioned in the atom-
iser and the participant started using it. The battery was
fully charged before being used by each subject.
Study protocol
Participants presented to the echocardiographic labora-
tory after fasting and refraining from alcohol and
caffeine consumption for 4 hours; they were also asked
to refrain from smoking and electronic cigarette use for
4 hours before the study.
Participants were allowed to rest for 5 minutes before
initiating the echocardiographic examination. A baseline
echocardiographic examination was performed in smokers,
who were then transferred to a room next to the echocar-
diography laboratory and smoked 1 tobacco cigarette. For
electronic cigarette users, after the baseline echocardio-
gram they were asked to use the electronic cigarette device
ad lib for 7 minutes in another room which was not used
by smokers, to avoid environmental exposure to smoke.
Subsequently, all participants returned to the echocardiog-
raphy laboratory and, after 5 minutes of rest, a second
echocardiogram was performed in both groups.
Heart rate and BP were measured before and during
each echocardiographic examination. The Brinkman index
was calculated (product of number of cigarettes smoked
daily and years of smoking) according to participants’ self-
report. Echocardiograms were performed using a com-
mercially available system (Vivid 7, GE Vingmed, Horten,
Norway). Studies were digitally recorded on hard disk foroffline analysis using dedicated software (Echopac, GE
Medical Systems, Horten, Norway) by a single, blinded to
the protocol, experienced echocardiographer. Reported
values represent the average of 3 consecutive beats.
Two-dimensional echocardiographic measurements
The echocardiographic examinations were performed
according to recent guidelines [9]. LV dimensions, septal
and posterior wall thickness were measured from standard
2-dimensional images at parasternal long-axis view. LV
mass was indexed to body-surface area. Ejection fraction
was evaluated from the apical four and two-chamber
views using the Simpson’s rule [10]. Left atrial (LA)
antero-posterior diameter was also measured.
Doppler flow and tissue Doppler velocity measurements
From transmitral flow measurements, peak early (E) and
late (A) velocities, their ratio (E/A) and E wave deceleration
time (DT) were estimated. Ejection time was estimated by
recording LV outflow tract velocity. By simultaneously re-
cording aortic and mitral flows using continuous-wave
Doppler the isovolumetric relaxation time (IVRT) was
measured, and was then corrected to heart rate by dividing
it with the square root of R-R interval (IVRTc).
Pulsed-wave Doppler tissue velocities were measured
by placing a 1.5 mm sample volume at the lateral, septal,
anterior and inferior insertion sites of the mitral leaflets.
Systolic (Sm), early diastolic (Em) and late diastolic
(Am) peak velocities were measured and averaged from
the 4 sites. The ratio of early-to-late annular velocity
(Em/Am) and early mitral flow to early diastolic mitral
annular velocity (E/Em) were also determined.
Myocardial performance index was measured by
two methods (Figure 2): using Doppler flow velocity
Figure 2 Myocardial performance index, measured by two methods: (1) Doppler flow velocity measurements of mitral inflow and left
ventricular outflow tract; the index was derived by the formula: MPI = (a-b)/b, and (2) Pulsed-wave tissue Doppler measurements of
mitral annulus velocity; the index was derived from the formula: MPIt = (a’-b’)/b’.
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using pulsed-wave tissue Doppler measurements of
mitral annulus velocities (MPIt) [12].
To check for reproducibility of measurements, the
intraobserver mean percent error (the absolute differ-
ence between two measurements divided by their mean)
was calculated from 10 randomly selected studies 15 days
later, analyzed by the same blinded echocardiographer
who performed all measurements. The results were
5.1 ± 2.9% for IVRT, 3.5 ± 2.5% for MPI, 3.6 ± 2.2% for
MPIt and 2.6 ± 1.9% for Em.
Longitudinal deformation measurements
Longitudinal deformation measurements were performed
by analyzing two-dimensional echocardiographic images
using the method of speckle tracking echocardiography
[13]. End-diastole was defined as the peak of the R wave
on the electrocardiographic trace; end-systole (aortic valve
closure) was defined from pulsed-wave Doppler tracing at
the LV outflow tract as the end of systolic forward flow.
Subjects with inadequate tracking of more than one LV
segment in each view were excluded from the analysis. By
averaging segmental values in all views, end-systolic global
strain (GS) was measured. Global peak longitudinal sys-
tolic (SRs), early diastolic (SRe) and late diastolic (SRa)
strain rate were measured. The intraobserver mean per-
cent error of longitudinal deformation measurements in
our laboratory was 3.1 ± 1.5% for GS, 3.6 ± 1.8% for SRs,
3.9 ± 1.9% for SRe and 3.6 ± 2.0% for SRa.
Statistical analysis
The Kolmogorov-Smirnov tests were applied to assess
the normality of data; all parameters were normally
distributed except from daily cigarette consumption.
Continuous variables were expressed as mean ± SD ormedian (interquartile range). Categorical variables were
expressed as number (percentage). Inter-group compari-
sons of baseline characteristics data were made by un-
paired Student’s t-test and Mann–Whitney test; Fisher’s
exact test was used for categorical variables.
Repeated measurements analysis of variance (ANOVA)
was used in order to evaluate changes in parameters before
and after smoking one cigarette or using the electronic
cigarette device (before-use and after-use measurements).
Changes in echocardiographic and deformation parameters
that were significantly different between the two study
groups from analysis of variance were further analyzed
using linear regression analyses, in order to find if the ef-
fect of smoking was significant after adjusting for changes
in heart rate and systolic BP. For every parameter, a differ-
ent linear regression analysis was performed. Change (Δ)
in parameter was the dependent variable; group (SM vs.
ECIG) and change in heart rate and systolic BP were the
independent variables. All P values reported are two-tailed.
Statistical significance was set at 0.05 and analyses were
conducted using SPSS statistical software (version 18.0,
SPSS Inc., Chicago, USA).
A repeated measures ANOVA power analysis was con-
ducted. For this design, 76 participants (40 in the
smokers group and 36 in the electronic cigarette users
group) achieved a power of 0.90 for the between-
subjects main effect at an effect size of 0.30; a power of
0.90 for the within-subjects main effect at an effect size
of 0.15; and a power of 0.90 for the interaction effect at
an effect size of 0.15.
Results
Both groups had similar baseline characteristics (Table 1).
Electronic cigarette users had quit smoking for 97 ±
50 days and were using electronic cigarettes for 100 ±







Males n (%) 32 (88.9) 36 (90) 1.000a
Age (years) 36 ± 5 35 ± 5 0.764
Body mass index (kg/m2) 24.8 ± 2.3 25.3 ± 2.4 0.304
Body surface area (m2) 2.03 ± 0.15 2.00 ± 0.18 0.322
Smoking duration (years) 16 ± 5 17 ± 5 0.571
Cigarette consumption (n/d)b 20 (20–26) 30 (20–35) 0.004c




Systolic BP (mmHg) 123.0 ± 9.8 123.9 ± 8.6 0.653
Diastolic BP (mmHg) 75.8 ± 5.6 75.6 ± 6.1 0.834
Heart rate (beats/m) 67.5 ± 7.9 67.1 ± 10.3 0.841
Pressure-rate product 8308 ± 1235 8312 ± 1363 0.989
Glucose (mmol/l) 4.51 ± 0.34 4.44 ± 0.35 0.410
Total cholesterol (mmol/l) 4.85 ± 0.21 4.77 ± 0.30 0.177
LDL cholesterol (mmol/l) 2.99 ± 0.23 2.91 ± 0.26 0.175
HDL cholesterol (mmol/l) 1.38 ± 0.15 1.38 ± 0.18 0.943
Triglycerides (mmol/l) 1.05 ± 0.14 1.04 ± 0.18 0.693
Ejection fraction (%) 63 ± 5 62 ± 4 0.463
LA diameter (mm) 35 ± 4 34 ± 3 0.359
LV mass index (g/m2) 64 ± 10 65 ± 13 0.663
BP, blood pressure, LVEDV, left ventricular end-diastolic volume; LVESV,
left ventricular end-systolic volume; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; LA, left atrium.
aFisher’s exact test; bValues expressed as median (interquartile range);
cMann-Whitney test; dDuration expressed in months.
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with Brinkman index 33% higher compared to smokers,
due to higher daily cigarette consumption when they
were smokers.
Changes in haemodynamic, Doppler echocardiography
and longitudinal deformation measurements for the study
groups are presented in Tables 2 and 3. Baseline measure-
ments were similar between groups for all parameters.
After-use values of systolic BP, heart rate and pressure-
rate product were elevated in the SM group but not in the
ECIG group (Table 2). The overall change from baseline
was significantly different between the two groups. In con-
trast, diastolic BP increased equally in both groups.
From Doppler flow echocardiographic measurements
(Table 2), E velocity and DT remained unchanged after
use in both groups. A velocity was increased and E/A
was decreased in SM, but the overall change was not sig-
nificantly different between the two groups (P = 0.317
and P = 0.053, respectively). IVRT, IVRTc and MPI were
increased after smoking one cigarette in the SM group,
and the degree of change was significantly differentbetween the two study groups (P = 0.001, P < 0.001 and
P = 0.001 respectively). The after-use levels of IVRTc and
MPI were greater in SM compared to ECIG, as was
shown by the between-groups analysis.
Concerning Doppler tissue velocitymeasurements (Table 3),
Sm and Am remained unchanged after use in both groups.
However, Em was significantly reduced in SM group after
smoking. It was lower when compared to ECIG after using
the device, and the degree of change was significantly dif-
ferent between the two groups (P < 0.001). Em/Am was re-
duced and E/Em was increased in SM, but the difference
of the overall change between the two groups was statisti-
cally significant for Em/Am only (P = 0.011). MPIt in-
creased after smoking in SM; the degree of change was
significantly different between the two groups (P < 0.001),
with after-use levels being significantly higher in SM com-
pared to ECIG (P = 0.019).
Longitudinal deformation measurements (Table 3) were
feasible in 37 electronic cigarette users and 34 smokers.
No difference in GS, SRs and SRa was observed in ECIG
and SM after use. However, SRe was significantly reduced
in SM post-smoking, with the degree of change being sta-
tistically significant between groups (P < 0.001).
The results of multiple linear regression analyses are
displayed in Table 4. Even after adjusting for changes in
systolic BP and heart rate, changes in IVRT, IVRTc, MPI,
Em, MPIt and SRe were significantly higher in SM group.
Discussion
This is the first study to examine the acute effects of
electronic cigarette use on myocardial function. No ad-
verse effects on LV myocardial function were observed
after using electronic cigarette with nicotine-containing
liquid for 7 minutes. On the contrary, significant changes
in diastolic function parameters were found after smoking
1 tobacco cigarette.
The acute adverse effects of smoking on myocardial relax-
ation were originally observed in coronary artery disease pa-
tients [14], with acute impairment of coronary vasomotion
implicated as the main cause [15]. Such effects on diastolic
function are also detected in healthy smokers [5-7] Cigarette
smoke contains significant amounts of free radicals, pro-
moting oxidative stress and inflammation [16] At the cellu-
lar level, decreased function of myocardial mitochondria
[17] and DNA damage [18] has been observed. These
mechanisms may be implicated in delaying myocardial re-
laxation from acute use and promoting atherosclerosis and
cardiovascular disease from chronic use. In this study, sev-
eral parameters commonly used for evaluating diastolic
function [19] and longitudinal deformation measurements
which are considered more sensitive in detecting pathology
[20] were significantly altered after smoking inhalation.
Electronic cigarettes were invented in 2003, but aware-
ness and use has significantly increased over the past
Table 2 Haemodynamic and Doppler flow measurements in electronic cigarette users (ECIG, n = 40) and smokers
(SM, n = 36), before and after device and cigarette use respectively
Parameter Before use After use Change P-valuea P-valueb
Systolic BP (mmHg)
ECIG 123.9 ± 8.6 124.6 ± 9.9 0.7 ± 4.6 0.374 < 0.001
SM 123.0 ± 9.8 129.6 ± 9.2 6.6 ± 5.2 < 0.001
P-valuec 0.653 0.025
Diastolic BP (mmHg)
ECIG 75.6 ± 6.1 78.5 ± 5.9 3.0 ± 3.6 < 0.001 0.079
SM 75.8 ± 5.6 80.2 ± 5.8 4.4 ± 3.3 < 0.001
P-valuec 0.834 0.209
Heart rate (beats/m)
ECIG 67.1 ± 10.3 67.5 ± 10.6 0.4 ± 4.8 0.649 < 0.001
SM 67.5 ± 7.9 73.5 ± 6.8 5.9 ± 4.7 < 0.001
P-valuec 0.841 0.005
Pressure-rate product
ECIG 8312 ± 1363 8397 ± 1462 84 ± 708 0.456 < 0.001
SM 8308 ± 1235 9556 ± 1084 1248 ± 840 < 0.001
P-valuec 0.989 < 0.001
E (cm/s)
ECIG 70.1 ± 12.5 71.4 ± 13.2 1.2 ± 5.0 0.130 0.132
SM 72.9 ± 8.5 72.2 ± 10.2 −0.6 ± 6.1 0.565
P-valuec 0.268 0.756
A (cm/s)
ECIG 51.1 ± 10.2 52.7 ± 9.8 1.6 ± 5.6 0.083 0.317
SM 50.4 ± 8.8 53.3 ± 9.1 2.9 ± 5.7 0.007
P-valuec 0.774 0.764
E/A
ECIG 1.41 ± 0.29 1.37 ± 0.26 −0.03 ± 0.14 0.171 0.053
SM 1.49 ± 0.32 1.39 ± 0.30 −0.10 ± 0.16 0.001
P-valuec 0.235 0.809
DT (ms)
ECIG 173 ± 11 174 ± 14 1 ± 8 0.581 0.570
SM 170 ± 16 172 ± 16 3 ± 10 0.086
P-valuec 0.448 0.719
IVRT (ms)
ECIG 74.6 ± 9.5 73.6 ± 9.9 −1.0 ± 5.7 0.275 0.001
SM 73.0 ± 8.7 77.7 ± 13.5 5.6 ± 9.2 < 0.001
P-valuec 0.450 0.132
IVRTc (ms)
ECIG 78.9 ± 11.8 77.7 ± 11.6 −1.2 ± 6.9 0.286 < 0.001
SM 77.3 ± 10.1 86.1 ± 16.4 10.4 ± 10.1 < 0.001
P-valuec 0.524 0.011
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Table 2 Haemodynamic and Doppler flow measurements in electronic cigarette users (ECIG, n = 40) and smokers
(SM, n = 36), before and after device and cigarette use respectively (Continued)
MPI
ECIG 0.39 ± 0.07 0.38 ± 0.06 −0.01 ± 0.04 0.330 0.001
SM 0.40 ± 0.05 0.43 ± 0.06 0.03 ± 0.04 0.002
P-valuec 0.355 0.001
BP, blood pressure; E, mitral flow early diastolic velocity; A, mitral flow late diastolic velocity; DT, deceleration time of early mitral flow; IVRT, isovolumetric
relaxation time; IVRTc, IVRT corrected to heart rate; MPI, myocardial performance index estimated by Doppler flow echocardiography.
aP-value for time effect.
bRepeated measurements ANOVA. Effects reported are significant differences between the two groups in the degree of change in each particular variable.
cP-value for group effect.
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does not involve combustion. However, lack of research
on their health effects has generated significant contro-
versy over their safety. FDA and WHO issued public
statements in 2009, expressing concern and recom-
mending that electronic cigarette use should be avoided.
WHO has specifically asked for studies to be performed
before regulation or even ban is imposed. Cahn and
Siegel summarized the results of 16 studies evaluating
the chemical composition of liquids used for electronic
cigarettes [22]. Nitrosamines were found in only two of
the studies, at levels similar to those present in nicotine
patch; a recent review indicated that the levels of nitro-
samines in electronic cigarettes were up to 1800 times
lower compared to tobacco cigarettes [23]. The main
constituents, besides nicotine, were propylene glycol and
glycerine, which are also present in tobacco cigarettes;
however, the combustion process from smoking leads to
production of acrolein, acetaldehyde and formaldehyde,
which promote oxidative stress and have cardiotoxic
properties [24]. In electronic cigarettes, such chemicals
may be formed from the heating process during liquid
evaporation; however, the levels found were lower com-
pared to tobacco cigarettes by orders of magnitude [25].
This may explain the results from laboratory studies, in
which electronic cigarette vapour was significantly less
cytotoxic compared to cigarette smoke on cultured cells
[26,27]. Cardiotoxic substances like nitrosamines, heavy
metals and polycyclic aromatic hydrocarbons were not de-
tected in the liquid used in this study [9]. These parame-
ters may explain the differences in diastolic function
observed between smokers and electronic cigarette users
after smoking and device use. Moreover, a study evalu-
ating the effects of smoking compared to nicotine deliv-
ered by gum showed that nicotine alone did not cause
acute changes in diastolic function [28]. It seems that
nicotine absorption rate is lower from electronic com-
pared to tobacco cigarette use [29], even when using
new-generation devices [30]; the difference in haemo-
dynamic response between the two groups may be attrib-
uted to this. However, haemodynamic parameters cannot
explain the differences in diastolic function parameters,since linear regression analyses revealed that changes in
Doppler and deformation parameters were associated with
cigarette smoking even after adjusting for changes in sys-
tolic BP and heart rate.
From a public health perspective, epidemiological
studies have shown that tobacco harm reduction strategy
and products may be promising regarding cardiovascular
disease risk reduction [31]. Electronic cigarettes are
unique since they are the only products that do not con-
tain tobacco, while they mimic the act of smoking and
provide motor and sensory stimulation. Thus, they may
deal with both the chemical (nicotine delivery) and be-
havioural components of cigarette addiction [22] and
studies indicate that they may be effective in promoting
smoking cessation [32,33]. This study provides the first
clinical evidence that electronic cigarettes have less acute
adverse effects on myocardial function when compared
to tobacco cigarettes.
Some limitations apply to this study. A small sample size
was studied, and examination focused only on immediate
effects. The results do not indicate that electronic ciga-
rettes are absolutely safe for the cardiovascular system.
Other parameters known to be adversely affected by acute
smoking, such as coronary microvascular and endothelial
function or vascular distensibility, were not examined.
Moreover, the parameters examined are affected mainly
by heart rate changes. Although heart rate was not in-
cluded as a covariate in the repeated-measures ANOVA,
the linear regression analysis showed that changes in dia-
stolic function were significantly different between groups
independently of the changes in heart rate and systolic BP.
This can be explained by the small difference in post-use
heart rate between groups of only 6 beats per minute.
Studies on long-term effects are necessary; however, more
time of use is needed before any such studies are pub-
lished since electronic cigarettes were introduced to the
market in recent years and there is a substantial delay be-
tween smoking initiation and development of clinically-
evident disease. We asked subjects to use the electronic
cigarette for 7 minutes. It is unknown whether more time
of use could have had a different impact. However, timing
was based on the approximate time of smoking 1 regular
Table 3 Tissue Doppler velocity and longitudinal deformation measurements in electronic cigarette users (ECIG, n = 40)
and smokers (SM, n = 36), before and after device and cigarette use respectively*
Parameter Before use After use Change P-valuea P-valueb
Sm (cm/s)
ECIG 9.7 ± 1.6 9.9 ± 1.6 0.2 ± 0.7 0.171 0.613
SM 9.7 ± 1.4 9.7 ± 1.5 −0.8 ± 1.1 0.571
P-valuec 0.896 0.723
Em (cm/s)
ECIG 12.7 ± 1.9 12.9 ± 2.1 0.2 ± 0.7 0.095 < 0.001
SM 12.8 ± 2.1 11.9 ± 1.5 −0.7 ± 1.4 < 0.001
P-valuec 0.892 0.032
Am (cm/s)
ECIG 9.7 ± 1.7 9.9 ± 1.6 0.2 ± 0.8 0.122 0.441
SM 9.3 ± 1.2 9.4 ± 1.3 0.1 ± 0.6 0.801
P-valuec 0.212 0.099
Em/Am
ECIG 1.34 ± 0.29 1.33 ± 0.28 −0.01 ± 0.13 0.540 0.011
SM 1.40 ± 0.28 1.30 ± 0.24 −0.08 ± 0.13 0.004
P-valuec 0.408 0.655
E/Em
ECIG 5.60 ± 1.04 5.61 ± 1.11 0.01 ± 0.47 0.869 0.052
SM 5.83 ± 0.95 6.10 ± 0.98 0.29 ± 0.74 0.021
P-valuec 0.311 0.044
MPIt
ECIG 0.48 ± 0.08 0.47 ± 0.09 −0.01 ± 0.04 0.080 < 0.001
SM 0.49 ± 0.06 0.52 ± 0.07 0.03 ± 0.05 0.004
P-valuec 0.654 0.019
GS (%)
ECIG −21.1 ± 1.9 −21.5 ± 1.6 −0.4 ± 1.2 0.059 0.087
SM −21.0 ± 2.6 −20.7 ± 3.1 0.2 ± 1.7 0.441
P-valuec 0.769 0.192
SRs (s−1)
ECIG −1.13 ± 0.10 −1.14 ± 0.11 −0.01 ± 0.07 0.362 0.613
SM −1.08 ± 0.13 −1.10 ± 0.13 −0.2 ± 0.1 0.150
P-valuec 0.059 0.115
SRe (s−1)
ECIG 1.47 ± 0.25 1.49 ± 0.23 0.01 ± 0.08 0.347 < 0.001
SM 1.43 ± 0.25 1.35 ± 0.24 −0.08 ± 0.12 < 0.001
P-valuec 0.493 0.022
SRa (s−1)
ECIG 0.88 ± 0.20 0.89 ± 0.18 0.01 ± 0.08 0.462 0.441
SM 0.86 ± 0.14 0.88 ± 0.14 0.03 ± 0.09 0.111
P-valuec 0.536 0.796
*Longitudinal deformation measurements were performed in 37 electronic cigarette users and 34 smokers.
Sm, mitral annulus systolic velocity; Em, mitral annulus early diastolic velocity; Am, mitral annulus late diastolic velocity; MPIt, myocardial performance index
estimated by tissue Doppler echocardiography; GS, global longitudinal strain; SRs, peak systolic strain rate; SRe, peak early diastolic strain rate; SRa, peak late
diastolic strain rate.
aP-value for time effect.
bRepeated measurements ANOVA. Effects reported are significant differences between the two groups in the degree of change in each particular variable.
cP-value for group effect.
Farsalinos et al. BMC Cardiovascular Disorders 2014, 14:78 Page 8 of 10
http://www.biomedcentral.com/1471-2261/14/78
Table 4 Results from linear regression analyses for the
effect of group (smokers vs. electronic cigarette users) on
changes (Δ) of Doppler echocardiography measurements,
after adjusting for changes in systolic blood pressure and
heart rate
Dependent variable β* SE** P-value
ΔIVRT (ms) 4.64 2.12 0.032
ΔIVRTc (ms) 5.46 2.34 0.022
ΔMPI 0.03 0.01 0.013
ΔEm (cm/s) −0.87 0.25 0.001
ΔMPIt 0.04 0.01 0.001
ΔSRe (s−1) −0.06 0.03 0.039
*Regression coefficient for the comparison of SM group to ECIG group,
adjusted for changes in systolic blood pressure and heart rate.
**Standard Error.
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cigarette while electronic cigarette users were asked to use
the device for a longer time. Additionally, experienced
users were examined, who use the device more intensively
than novice users [34]. Unfortunately, there are no other
means of comparing electronic with tobacco cigarette use.
Although plasma nicotine levels were not measured, the
haemodynamic response observed suggests that the nico-
tine delivery rate from electronic cigarettes is lower and
slower compared to tobacco cigarettes. This has been vali-
dated by studies performed recently [30,35]. The results of
this study are not necessarily applicable to all liquids avail-
able in the market. If non-pharmaceutical grade nicotine
is used, several tobacco impurities may be present and
inhaled by the user. The same applies for other liquid con-
stituents [21]. Finally, although all subjects were consid-
ered healthy based on history taking, clinical examination,
resting ECG and echocardiogram, it cannot be excluded
that some subjects may suffer from subclinical coronary
artery disease. However, there was no indication to per-
form any additional examinations in the study population.
Conclusions
Although acute smoking inhalation caused a delay in LV
myocardial relaxation in smokers, electronic cigarette
use was found to have no such immediate effects in daily
users of the device. This short-term beneficial profile of
electronic cigarette compared to smoking, although not
conclusive about its overall health-effects as a tobacco
harm reduction product, provides the first evidence
about the cardiovascular effects of this device. Since
awareness and use of electronic cigarettes are continu-
ously rising, more studies are urgently needed, focusing
on the pathophysiological mechanisms of disease where
smoking is implicated and ultimately on long-term ef-
fects. Such studies will provide additional scientific data
to public health authorities so that they decide on the
regulatory status of this product.Competing interests
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